Literature DB >> 34409525

Animal models for researching approaches to therapy of Duchenne muscular dystrophy.

M I Zaynitdinova1, A V Lavrov2, S A Smirnikhina2.   

Abstract

Duchenne muscular dystrophy (DMD) is a relatively widespread genetic disease which develops as a result of a mutation in the gene DMD encoding dystrophin. In this review, animal models of DMD are described. These models are used in preclinical studies to elucidate the pathogenesis of the disease or to develop effective treatments; each animal model has its own advantages and disadvantages. For instance, Caenorhabditis elegans, Drosophila melanogaster, and zebrafish (sapje) are suitable for large-scale chemical screening of large numbers of small molecules, but their disease phenotype differs from that of mammals. The use of larger animals is important for understanding of the potential efficacy of various treatments for DMD. While mdx mice have their advantages, they exhibit a milder disease phenotype compared to humans or dogs, making it difficult to evaluate the efficacy of new treatment for DMD. The disease in dogs and pigs is more severe and progresses faster than in mice, but it is more difficult to breed and obtain sufficient numbers of specimens in order to achieve statistically significant results. Moreover, working with large animals is also more labor-intensive. Therefore, when choosing the optimal animal model for research, it is worth considering all the goals and objectives.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Animal models; DMD; Duchenne muscular dystrophy; Dystrophin; Mdx mice

Mesh:

Year:  2021        PMID: 34409525     DOI: 10.1007/s11248-021-00278-3

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  121 in total

1.  In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide.

Authors:  R J Bartlett; S Stockinger; M M Denis; W T Bartlett; L Inverardi; T T Le; N thi Man; G E Morris; D J Bogan; J Metcalf-Bogan; J N Kornegay
Journal:  Nat Biotechnol       Date:  2000-06       Impact factor: 54.908

2.  Ringo, a Golden Retriever Muscular Dystrophy (GRMD) dog with absent dystrophin but normal strength.

Authors:  C E Ambrósio; M C Valadares; E Zucconi; R Cabral; P L Pearson; T P Gaiad; M Canovas; M Vainzof; M A Miglino; M Zatz
Journal:  Neuromuscul Disord       Date:  2008-07-29       Impact factor: 4.296

3.  Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy.

Authors:  E Araki; K Nakamura; K Nakao; S Kameya; O Kobayashi; I Nonaka; T Kobayashi; M Katsuki
Journal:  Biochem Biophys Res Commun       Date:  1997-09-18       Impact factor: 3.575

Review 4.  Duchenne muscular dystrophy--what causes the increased membrane permeability in skeletal muscle?

Authors:  David G Allen; Nicholas P Whitehead
Journal:  Int J Biochem Cell Biol       Date:  2010-11-21       Impact factor: 5.085

5.  In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.

Authors:  Yoshitsugu Aoki; Akinori Nakamura; Toshifumi Yokota; Takashi Saito; Hitoshi Okazawa; Tetsuya Nagata; Shin'ichi Takeda
Journal:  Mol Ther       Date:  2010-09-07       Impact factor: 11.454

6.  Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.

Authors:  Yoshitsugu Aoki; Toshifumi Yokota; Tetsuya Nagata; Akinori Nakamura; Jun Tanihata; Takashi Saito; Stephanie M R Duguez; Kanneboyina Nagaraju; Eric P Hoffman; Terence Partridge; Shin'ichi Takeda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

Review 7.  Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.

Authors:  David G Allen; Nicholas P Whitehead; Stanley C Froehner
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 8.  The importance of genetic diagnosis for Duchenne muscular dystrophy.

Authors:  Annemieke Aartsma-Rus; Ieke B Ginjaar; Kate Bushby
Journal:  J Med Genet       Date:  2016-01-11       Impact factor: 6.318

9.  Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.

Authors:  Yoshitsugu Aoki; Tetsuya Nagata; Toshifumi Yokota; Akinori Nakamura; Matthew J A Wood; Terence Partridge; Shin'ichi Takeda
Journal:  Hum Mol Genet       Date:  2013-07-23       Impact factor: 6.150

10.  In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse.

Authors:  Leonela Amoasii; Hui Li; Yu Zhang; Yi-Li Min; Efrain Sanchez-Ortiz; John M Shelton; Chengzu Long; Alex A Mireault; Samadrita Bhattacharyya; John R McAnally; Rhonda Bassel-Duby; Eric N Olson
Journal:  Nat Commun       Date:  2019-10-04       Impact factor: 14.919

View more
  2 in total

Review 1.  Histopathology of Duchenne muscular dystrophy in correlation with changes in proteomic biomarkers.

Authors:  Margit Zweyer; Hemmen Sabir; Paul Dowling; Stephen Gargan; Sandra Murphy; Dieter Swandulla; Kay Ohlendieck
Journal:  Histol Histopathol       Date:  2021-12-07       Impact factor: 2.303

Review 2.  Role of Regulatory T Cells in Skeletal Muscle Regeneration: A Systematic Review.

Authors:  Jaciara F G Gama; Rayza D Romualdo; Mayara L de Assis; Luana M de Oliveira; Thereza Quírico-Santos; Luiz A Alves; Jussara Lagrota-Candido
Journal:  Biomolecules       Date:  2022-06-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.